Acquisition centres on promising narcolepsy drug as orexin receptor space draws intense pharma interest

Eli Lilly (NYSE: LLY) has agreed to acquire Centessa Pharmaceuticals in a deal worth up to $47 per share, placing a substantial wager on a novel class of sleep disorder treatments and deepening the US drugmaker's push into neuroscience at a time of fierce competition for differentiated pipeline assets.

The Indianapolis-based company will pay $38 per share in cash upfront, with a contingent value right of up to a further $9 per share tied to the performance of cleminorexton, Centessa's lead compound and the asset at the heart of the transaction. Centessa shares surged 44 per cent to close at $39.72 on the news, reflecting both the premium on offer and investor confidence that the contingent component is achievable.

Cleminorexton is an orexin-2 receptor agonist in development for narcolepsy and related sleep disorders — a mechanism that has attracted rapidly growing pharmaceutical interest following the blockbuster commercial performance of orexin antagonists in insomnia. The therapeutic logic, as researchers and investors have come to appreciate, operates symmetrically: drugs that block orexin signalling help patients fall asleep; drugs that stimulate it promote wakefulness. Lilly is betting that cleminorexton can do the latter with a precision and tolerability profile that sets it apart from existing treatments.

A mechanistically compelling target

Narcolepsy is a debilitating neurological condition characterised by excessive daytime sleepiness, sudden muscle weakness and disrupted nocturnal sleep. Its underlying cause in the most common form of the disease is the selective destruction of orexin-producing neurons in the hypothalamus by an autoimmune process, leaving patients with a near-total deficit of the neuropeptide responsible for sustaining arousal and wakefulness.

Current standard-of-care treatments, including stimulants and sodium oxybate, address symptoms without targeting the underlying neurochemical deficit. An OX2R agonist capable of directly substituting for the lost orexin signal represents a mechanistically cleaner and potentially more effective approach — one that the field has long sought but struggled to prosecute given the complexity of designing small molecules that activate, rather than block, receptor signalling.

"The orexin system is one of the most important regulatory networks in sleep-wake biology," said one neuroscience analyst at a London-based investment bank. "Getting an agonist with the right selectivity and brain penetration profile has been genuinely hard. If cleminorexton has cracked that, the commercial opportunity is substantial."

Strategic fit for Lilly's neuroscience ambitions

For Lilly, the acquisition adds a sleep architecture franchise to a neuroscience pipeline that has expanded aggressively in recent years. The company already has significant programmes in Alzheimer's disease, pain and migraine, and has positioned itself as one of the sector's most productive development organisations — a reputation burnished by the commercial success of its GLP-1 obesity and diabetes therapies, which have generated the cash flows to fund ambitious dealmaking.

Sleep disorders represent a large and underserved market. Narcolepsy alone affects an estimated three million people in the United States and Europe, with diagnosis rates that remain low relative to true prevalence, suggesting significant room for market expansion as awareness and therapeutic options improve. The broader sleep disorder landscape — encompassing idiopathic hypersomnia and other conditions of excessive daytime sleepiness — extends the addressable opportunity further.

The contingent value right structure reflects a degree of clinical pragmatism on Lilly's part. By tying a portion of the consideration to future milestones, the company shares residual development risk with Centessa shareholders while still offering a headline number generous enough to secure the board's recommendation.

Competition in the orexin space intensifies

Lilly's move arrives as several other large pharmaceutical companies circle the orexin agonist space. Takeda, Jazz Pharmaceuticals and a clutch of well-funded biotechs are pursuing related programmes, making the acquisition of a potentially best-in-class asset a matter of strategic urgency as much as scientific conviction.

Whether cleminorexton ultimately delivers on the contingent value right will depend on late-stage clinical data still to come. But in securing the asset, Lilly has ensured it will not be watching from the sidelines if the orexin agonist hypothesis proves out — a calculation that, for one of the industry's most acquisitive companies, appears entirely characteristic.